Biopharma news, November 8, 2026
The most important drug and company news of November 8, 2026, ranked, each linked to its Gosset profiles.
Pivotal readout
Novartis pelacarsen cuts Lp(a) by 78% but fails to reduce heart events
Full Lp(a)HORIZON results in 8,323 patients showed TQJ230 sharply lowered lipoprotein(a) yet left the composite of cardiovascular events unchanged versus placebo. Injection-site and flu-like reactions were more common, and 19 anaphylaxis cases occurred on the drug. Novartis had disclosed the topline miss in September and wrote down the asset.
Source types: News article. Sources are available to Gosset users. Log in to see them.
Clinical readout
Allergan Aesthetics reports facial satisfaction gains in GLP-1 users
Two open-label studies tested neurotoxin, filler and skincare treatment in adults taking GLP-1 drugs. In one, 30 participants reported a 42.4-point average rise in satisfaction with their facial appearance; an interim look at 25 patients in the other showed a 39.6-point gain at three months. Most treatment-related side effects were mild.
Source types: Press release. Sources are available to Gosset users. Log in to see them.
Clinical readout
J&J's dual bispecific regimen lowers PSA in most treated prostate cancer patients
Among 15 heavily treated patients in a first-in-human trial, 11 saw PSA fall by at least half on pasritamig plus JNJ-9401, and seven by 90% or more. No grade 3 or worse treatment-related side effects occurred; three patients had mild cytokine release syndrome. The pairing is now being tested in KLK2-comPAS, a phase 3 trial.
- Drugpasritamig
- TargetKallikrein-related peptidase 2
- TargetT cell surface glycoprotein CD3
- TrialNCT06095089
- TrialNCT07164443
Source types: Press release. Sources are available to Gosset users. Log in to see them.
Clinical readout
Single dose of CIDEB siRNA cuts liver fat up to 80% in MASLD trial
In a first-in-human study of 40 people, one dose of the CIDEB-targeting siRNA lowered liver fat by 58% to 80% at week 36, depending on dose, versus 2.9% on placebo. Liver fat returned to normal in 62% of treated participants. The candidate is moving into later-stage trials, and Regeneron will review its MASH pipeline on November 10.
Source types: Press release. Sources are available to Gosset users. Log in to see them.
Pivotal readout
GSK's bepirovirsen cure holds for most patients a year after stopping treatment
Final data from the phase 3 B-Well 1 and 2 studies showed 211 of 232 patients who reached functional cure still had it at week 96, nearly a year after all hepatitis B therapy ended. At week 72, 19% of treated patients were cured versus none on placebo. Two Chinese marketing applications remain under priority review.
Source types: News article. Sources are available to Gosset users. Log in to see them.
Pivotal readout
Brii picks hepatitis B cure regimen for registration study after phase 2b
In the single-arm ENRICH study of 148 patients, 32.4% remained free of hepatitis B surface antigen six months after stopping BRII-179 priming followed by elebsiran and interferon. Brii chose this sequence for a potential registration trial after early talks with China's regulator. It will not fund phase 3 work with elebsiran until its arbitration with Vir is settled.
Source types: News article. Sources are available to Gosset users. Log in to see them.
Clinical readout
BCMA T-cell engager velinotamig shows early activity in refractory lupus
Early results from an ongoing phase 1b/2a trial showed SLEDAI-2K dropped by four points or more in eight of the nine patients with refractory lupus who could be assessed. Four of seven with heavy baseline proteinuria reached complete renal response by week 24. Of 12 treated patients, two had low-grade cytokine release syndrome and none had dose-limiting toxicity.
Source types: Press release. Sources are available to Gosset users. Log in to see them.
Clinical readout
AusperBio's AHB-137 keeps hepatitis B functional cure 15 months off therapy
In long-term follow-up of phase 2 responders, every participant reaching the 15-month mark after stopping all hepatitis B treatment remained functionally cured, nine pretreated and six treatment-naive. No clinical relapse or new safety signal was seen. The antisense drug is in phase 3 in China.
- DrugAHB-137
- CompanyAusperBio
- TargetHepatitis B virus messenger RNAs at three well-conserved genomic regions across multiple HBV genotypes
Source types: Press release. Sources are available to Gosset users. Log in to see them.
Clinical readout
Cabaletta's rese-cel keeps autoimmune patients off immunomodulators for a year
In phase 1/2 studies of the CAR-T therapy rese-cel, all six evaluable dermatomyositis patients held their responses for a year without immunomodulators, and all five biopsied lupus nephritis patients reached drug-free remission. Most of the 71 treated patients had no or grade 1 cytokine release syndrome. Cabaletta expects registrational myositis data in late 2027.
Source types: Press release. Sources are available to Gosset users. Log in to see them.